Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

ClinicalTrials.gov ID: NCT04076462

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04076462. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.

Study identification

NCT ID
NCT04076462
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Camurus AB
Industry
Enrollment
72 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 19, 2019 (Actual)
Primary completion
May 2, 2023 (Actual)
Completion
May 2, 2023 (Actual)
Last update posted
Aug 20, 2026

2019 – 2023

United States locations

U.S. sites
12
U.S. states
10
U.S. cities
12
Facility City State ZIP Site status
UCLA Department of Medicine Division of Endocrinology Los Angeles California 90095 —
Stanford University Medical Center Palo Alto California 94305 —
Prufen Clinical Research LLC Miami Florida 33130 —
University of Michigan Ann Arbor Michigan 48106 —
Mayo Clinic Rochester Minnesota 55905 —
Washington University in St. Louis, School of Medicine St Louis Missouri 63110 —
Palm Research Center Las Vegas Nevada 89148 —
Columbia University Medical Center New York New York 10018 —
University of Cincinnati Cincinnati Ohio 45267 —
Thomas Jefferson University Philadelphia Pennsylvania 19107 —
Allegheny Endocrinology Associates Pittsburgh Pennsylvania 15212 —
Research Institute of Dallas Dallas Texas 75231 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04076462, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 20, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.